Vaccine 90% effective in Phase 3 trial: Pfizer

A vaccine jointly developed by Pfizer and BioNTech was 90 percent effective in preventing COVID-19 infections in ongoing Phase 3 trials, the companies announced Monday. The statement was released as coronavirus cases are soaring across the world, and European stock markets and oil prices jumped on the news. According to preliminary findings, protection in patients was achieved seven days after the second of two doses, and 28 days after the first.